JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Italy Fines Apple €98.6 Million Over App Store Dominance 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
REHOVOT, Israel and BRIDGEWATER, N.J., July 26, 2017 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the three and six months ended June 30, 2017, and will host a corporate update conference call and webcast at 8:30am Eastern Time on Wednesday, August 9, 2017.
| Conference Call & Webcast | |
| Wednesday, August 9, 2017 @ 8:30 am Eastern Time | |
| Toll Free: | 877-780-3381 |
| International: | 913-312-1403 |
| Conference ID: | 2390109 |
| Webcast: | http://public.viavid.com/index.php?id=125169 |
| Replays, Available through August 23rd: | |
| Toll-Free: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 2390109 |
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
For more information, please visit www.foamixpharma.com.
Contact: Ilan Hadar, Country Manager & CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 [email protected] US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 [email protected]
